Abstract:Abstract Background Recently, a variety of clinical trials have shown that apatinib, a small-molecule anti-angiogenic drug, exerts promising inhibitory effects on multiple solid tumors, including non-small cell lung cancer (NSCLC). However, the underlying molecular mechanism of apatinib on NSCLC remains unclear. Methods MTT, EdU, AO/EB staining, TUNEL staining, flow cytometry, colony formation assays were performed to investigate the effects of apatinib on cell proliferation, cell cycle distribution, apoptosis and cancer stem like properties. Wound healing and transwell assays were conducted to explore the role of apatinib on migration and invasion. The regulation of apatinib on VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling were detected. Furthermore, we collected conditioned medium (CM) from A549 and H1299 cells to stimulate phorbol myristate acetate (PMA)-activated THP-1 cells, and examined the effect of apatinib on PD-L1 expression in macrophages. The Jurkat T cells and NSCLC cells co-culture model was used to assess the effect of apatinib on T cells activation. Subcutaneous tumor formation models were established to evaluate the effects of apatinib in vivo. Histochemical, immunohistochemical staining and ELISA assay were used to examine the levels of signaling molecules in tumors. Results We showed that apatinib inhibited cell proliferation and promoted apoptosis in NSCLC cells in vitro. Apatinib induced cell cycle arrest at G1 phase and suppressed the expression of Cyclin D1 and CDK4. Moreover, apatinib upregulated Cleaved Caspase 3, Cleaved Caspase 9 and Bax, and downregulated Bcl-2 in NSCLC cells. The colony formation ability and the number of CD133 positive cells were significantly decreased by apatinib, suggesting that apatinib inhibited the malignant and stem-like features of NSCLC cells. Mechanistically, apatinib inhibited PD-L1 and c-Myc expression by targeting VEGFR2/STAT3 signaling. Apatinib also inhibited PD-L1 expression in THP-1 derived macrophages stimulated by CM from NSCLC cells. Furthermore, apatinib pretreatment increased CD69 expression and IFN-γ secretion in stimulated Jurkat T cells co-cultured with NSCLC cells. Apatinib also promoted ROS production and inhibited Nrf2 and p62 expression, leading to the autophagic and apoptotic cell death in NSCLC. Moreover, apatinib significantly inhibited tumor growth in vivo. Conclusion Our data indicated that apatinib induced autophagy and apoptosis in NSCLC via regulating VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling.

Apatinib Enhances Antitumour Activity of EGFR-TKIs in Non-Small Cell Lung Cancer with EGFR-TKI Resistance

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

EGFR-TKI Rechallenged Treatment Combined with Apatinib in Non-Small Cell Lung Cancer with EGFR-TKI Resistance.

Low Dose of Apatinib in Treating Chemotherapy and EGFR-TKI Refractory Non-Small Cell Lung Cancer A Case Report

Apatinib Enhances Chemosensitivity of ABT-199 in Diffuse Large B-cell Lymphoma

Apatinib added when NSCLC patients get slow progression with EGFR-TKI: A prospective, single-arm study

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

Apatinib with First-Generation EGFR-TKIs As Second-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer with Acquired Resistance: a Retrospective Case Series Analysis

Clinical efficacy of Apatinib combined with Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) in nonsmall cell lung cancer after EGFR-TKI resistance

Combination Therapy of Apatinib with Icotinib for Primary Acquired Icotinib Resistance in Patients with Advanced Pulmonary Adenocarcinoma with EGFR Mutation.

Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review

Long-term Progression-Free Survival of Third-Line Apatinib in Lung Squamous Cell Carcinoma

Apatinib Alone or Combined with Radiation Therapy As a Salvage Treatment in Advanced Non-Small Cell Lung Cancer Failed from Two or More Lines of Prior Chemotherapy or Molecular Targeted Therapy

Apatinib-induced NF-κB Inactivation Sensitizes Triple-Negative Breast Cancer Cells to Doxorubicin.

Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.

Phase I Study of Apatinib Combined with Docetaxel in EGFR-negative Advanced Non-Small Cell Lung Cancer (NSCLC).

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells

P1.01-90 A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) As Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)

BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

A Phase II, Multicenter, Placebo-Controlled Trial of Apatinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) after Two Previous Treatment Regimens.